The Manufacturers Life Insurance Company Lowers Position in Guardant Health, Inc. (NASDAQ:GH)

The Manufacturers Life Insurance Company trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GHFree Report) by 6.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,716 shares of the company’s stock after selling 38,432 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.45% of Guardant Health worth $14,329,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Eaton Financial Holdings Company LLC acquired a new position in Guardant Health in the 4th quarter worth about $2,183,000. Hsbc Holdings PLC raised its stake in shares of Guardant Health by 151.0% during the 4th quarter. Hsbc Holdings PLC now owns 43,532 shares of the company’s stock worth $1,182,000 after buying an additional 26,191 shares during the period. TCW Group Inc. lifted its position in shares of Guardant Health by 23.3% during the 4th quarter. TCW Group Inc. now owns 133,660 shares of the company’s stock valued at $3,616,000 after buying an additional 25,231 shares in the last quarter. US Bancorp DE grew its stake in Guardant Health by 211.0% in the 4th quarter. US Bancorp DE now owns 38,076 shares of the company’s stock valued at $1,030,000 after acquiring an additional 25,832 shares during the period. Finally, Assetmark Inc. increased its holdings in Guardant Health by 38.2% in the 4th quarter. Assetmark Inc. now owns 17,199 shares of the company’s stock worth $465,000 after acquiring an additional 4,758 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Trading Down 1.2 %

Shares of NASDAQ GH opened at $28.67 on Monday. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. The stock has a market capitalization of $3.51 billion, a PE ratio of -7.31 and a beta of 1.15. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $41.06. The stock has a fifty day simple moving average of $21.44 and a 200-day simple moving average of $22.50.

Guardant Health (NASDAQ:GHGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) EPS for the quarter, meeting the consensus estimate of ($0.94). The business had revenue of $168.49 million during the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. On average, equities analysts forecast that Guardant Health, Inc. will post -3.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GH. Jefferies Financial Group began coverage on Guardant Health in a report on Monday, June 3rd. They issued a “buy” rating and a $32.00 price objective on the stock. Canaccord Genuity Group increased their price objective on Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. lowered their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. Finally, Stephens restated an “overweight” rating and set a $44.00 price target on shares of Guardant Health in a research report on Friday, May 24th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.91.

View Our Latest Stock Report on GH

Insider Buying and Selling at Guardant Health

In other news, insider Kumud Kalia bought 2,187 shares of Guardant Health stock in a transaction that occurred on Monday, March 18th. The shares were purchased at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares in the company, valued at $226,706.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is owned by corporate insiders.

About Guardant Health

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Further Reading

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.